The role of vitamin D in vascular calcification in chronic kidney disease

Godwin O. Wolisi, Sharon Moe

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Vascular calcification is a significant cause of morbidity and mortality in patients with chronic kidney disease (CKD). Disorders of mineral metabolism are likely involved in the pathogenesis of vascular calcification. Calcitriol and its analogs are effective in suppressing parathyroid hormone levels in patients with secondary hyperparathyroidism and CKD, but experimental studies demonstrate that these drugs can act directly on vascular smooth muscle cells. In some in vitro studies and in animal models of CKD, calcitriol has induced vascular calcification. Newer analogs of vitamin D appear to be less likely to induce vascular calcification, although published data are scarce. However, there is really no clear evidence in dialysis patients that calcitriol or analog administration is directly responsible for the induction of vascular calcification. However, indirectly, by oversuppression of parathyroid hormone (PTH) and induction of a low-turnover bone disease state, or by increased calcium-phosphorus product, the administration of calcitriol or its analogs may contribute to vascular calcification in patients with CKD. However, prospective randomized trials in CKD patients are necessary to fully understand the impact of calcitriol and analog therapy on vascular calcification.

Original languageEnglish
Pages (from-to)307-314
Number of pages8
JournalSeminars in Dialysis
Volume18
Issue number4
DOIs
StatePublished - Jul 2005

Fingerprint

Vascular Calcification
Chronic Renal Insufficiency
Vitamin D
Calcitriol
Parathyroid Hormone
Secondary Hyperparathyroidism
Bone Diseases
Vascular Smooth Muscle
Phosphorus
Smooth Muscle Myocytes
Minerals
Dialysis
Animal Models
Calcium
Morbidity
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nephrology

Cite this

The role of vitamin D in vascular calcification in chronic kidney disease. / Wolisi, Godwin O.; Moe, Sharon.

In: Seminars in Dialysis, Vol. 18, No. 4, 07.2005, p. 307-314.

Research output: Contribution to journalArticle

@article{c9abe5738a7b43f0821d4f7f72673a7f,
title = "The role of vitamin D in vascular calcification in chronic kidney disease",
abstract = "Vascular calcification is a significant cause of morbidity and mortality in patients with chronic kidney disease (CKD). Disorders of mineral metabolism are likely involved in the pathogenesis of vascular calcification. Calcitriol and its analogs are effective in suppressing parathyroid hormone levels in patients with secondary hyperparathyroidism and CKD, but experimental studies demonstrate that these drugs can act directly on vascular smooth muscle cells. In some in vitro studies and in animal models of CKD, calcitriol has induced vascular calcification. Newer analogs of vitamin D appear to be less likely to induce vascular calcification, although published data are scarce. However, there is really no clear evidence in dialysis patients that calcitriol or analog administration is directly responsible for the induction of vascular calcification. However, indirectly, by oversuppression of parathyroid hormone (PTH) and induction of a low-turnover bone disease state, or by increased calcium-phosphorus product, the administration of calcitriol or its analogs may contribute to vascular calcification in patients with CKD. However, prospective randomized trials in CKD patients are necessary to fully understand the impact of calcitriol and analog therapy on vascular calcification.",
author = "Wolisi, {Godwin O.} and Sharon Moe",
year = "2005",
month = "7",
doi = "10.1111/j.1525-139X.2005.18407.x",
language = "English",
volume = "18",
pages = "307--314",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The role of vitamin D in vascular calcification in chronic kidney disease

AU - Wolisi, Godwin O.

AU - Moe, Sharon

PY - 2005/7

Y1 - 2005/7

N2 - Vascular calcification is a significant cause of morbidity and mortality in patients with chronic kidney disease (CKD). Disorders of mineral metabolism are likely involved in the pathogenesis of vascular calcification. Calcitriol and its analogs are effective in suppressing parathyroid hormone levels in patients with secondary hyperparathyroidism and CKD, but experimental studies demonstrate that these drugs can act directly on vascular smooth muscle cells. In some in vitro studies and in animal models of CKD, calcitriol has induced vascular calcification. Newer analogs of vitamin D appear to be less likely to induce vascular calcification, although published data are scarce. However, there is really no clear evidence in dialysis patients that calcitriol or analog administration is directly responsible for the induction of vascular calcification. However, indirectly, by oversuppression of parathyroid hormone (PTH) and induction of a low-turnover bone disease state, or by increased calcium-phosphorus product, the administration of calcitriol or its analogs may contribute to vascular calcification in patients with CKD. However, prospective randomized trials in CKD patients are necessary to fully understand the impact of calcitriol and analog therapy on vascular calcification.

AB - Vascular calcification is a significant cause of morbidity and mortality in patients with chronic kidney disease (CKD). Disorders of mineral metabolism are likely involved in the pathogenesis of vascular calcification. Calcitriol and its analogs are effective in suppressing parathyroid hormone levels in patients with secondary hyperparathyroidism and CKD, but experimental studies demonstrate that these drugs can act directly on vascular smooth muscle cells. In some in vitro studies and in animal models of CKD, calcitriol has induced vascular calcification. Newer analogs of vitamin D appear to be less likely to induce vascular calcification, although published data are scarce. However, there is really no clear evidence in dialysis patients that calcitriol or analog administration is directly responsible for the induction of vascular calcification. However, indirectly, by oversuppression of parathyroid hormone (PTH) and induction of a low-turnover bone disease state, or by increased calcium-phosphorus product, the administration of calcitriol or its analogs may contribute to vascular calcification in patients with CKD. However, prospective randomized trials in CKD patients are necessary to fully understand the impact of calcitriol and analog therapy on vascular calcification.

UR - http://www.scopus.com/inward/record.url?scp=23844437946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844437946&partnerID=8YFLogxK

U2 - 10.1111/j.1525-139X.2005.18407.x

DO - 10.1111/j.1525-139X.2005.18407.x

M3 - Article

C2 - 16076354

AN - SCOPUS:23844437946

VL - 18

SP - 307

EP - 314

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 4

ER -